-
Speaker
List
Print
-
All Conference Hall No.1（2F） Conference Hall No.5-A（1F） Conference Hall No.5-B（1F） Conference Hall No.5-C（1F） Conference Hall No.5-D（1F） Conference Hall No.2-A（2F） Conference Hall No.2-B（2F） Conference Hall No.2-C（2F） Conference Hall No.2-AB（2F） Conference Hall No.3（Vascular care）（1F） Convention Hall No.2（2F） Conference Hall 201-A（2F） Conference Room 201-AB（2F） Conference Room 201-ABC（2F） Conference Room 201-BC（2F） Conference Room 201-D（2F） Conference Room 201-CD（2F） Coference Room No.307（3F） Conference Room No.308（3F） Conference Hall No.2-VIP-room-A（2F） Electronic Poster Machine：Conference Hall No.4（1F） Satellite Symposium
|
15:20-16:40
What is new in heparin use（Simultaneous Interpretation ）
Moderator: Debra A. Hoppensteadt United States , Shaker Mousa United States , Yiming Yao China 主持: Debra A. Hoppensteadt United States , Shaker Mousa United States , 姚亦明 China |
|||||
|---|---|---|---|---|---|
| NO./编号 | Time/时间 | Type/类型 | Subject/题目 | Speaker/讲者 | |
| 1 | 15:20-15:32 | Symposium |
Diversification of Heparins! What are the challenges? |
Debra A. Hoppensteadt United States |
|
| 2 | 15:32-15:44 | Symposium |
Heparin related glycosaminoglycans：Clinical use and future developments |
Shaker Mousa United States |
|
| 3 | 15:44-15:56 | Symposium |
Rationale for the therapeutic effects of Sulodexide and Danaparoid |
Jawed Fareed United States |
|
| 4 | 15:56-16:08 | Symposium |
Heparins and recanalization |
Pavel Poredos Slovenia |
|
| 5 | 16:08-16:20 | Symposium |
Heparins and Related Drugs in the Era of New Anticoagulants |
Jawed Fareed United States |
|
| 6 | 16:20-16:40 |
Discussion |
|||
Announcement